173 related articles for article (PubMed ID: 22739139)
1. Equivalent dynamic human brain NK1-receptor occupancy following single-dose i.v. fosaprepitant vs. oral aprepitant as assessed by PET imaging.
Van Laere K; De Hoon J; Bormans G; Koole M; Derdelinckx I; De Lepeleire I; Declercq R; Sanabria Bohorquez SM; Hamill T; Mozley PD; Tatosian D; Xie W; Liu Y; Liu F; Zappacosta P; Mahon C; Butterfield KL; Rosen LB; Murphy MG; Hargreaves RJ; Wagner JA; Shadle CR
Clin Pharmacol Ther; 2012 Aug; 92(2):243-50. PubMed ID: 22739139
[TBL] [Abstract][Full Text] [Related]
2. Fosaprepitant dimeglumine (MK-0517 or L-785,298), an intravenous neurokinin-1 antagonist for the prevention of chemotherapy induced nausea and vomiting.
Van Belle SJ; Cocquyt V
Expert Opin Pharmacother; 2008 Dec; 9(18):3261-70. PubMed ID: 19040346
[TBL] [Abstract][Full Text] [Related]
3. Fosaprepitant: a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Rev Anticancer Ther; 2008 Nov; 8(11):1733-42. PubMed ID: 18983233
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic evaluation of fosaprepitant dimeglumine.
Colon-Gonzalez F; Kraft WK
Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1277-86. PubMed ID: 20795794
[TBL] [Abstract][Full Text] [Related]
5. Fosaprepitant (MK-0517): a neurokinin-1 receptor antagonist for the prevention of chemotherapy-induced nausea and vomiting.
Navari RM
Expert Opin Investig Drugs; 2007 Dec; 16(12):1977-85. PubMed ID: 18042005
[TBL] [Abstract][Full Text] [Related]
6. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
Ottoboni T; Keller MR; Cravets M; Clendeninn N; Quart B
Drug Des Devel Ther; 2018; 12():429-435. PubMed ID: 29535504
[TBL] [Abstract][Full Text] [Related]
7. Tolerability of fosaprepitant and bioequivalency to aprepitant in healthy subjects.
Lasseter KC; Gambale J; Jin B; Bergman A; Constanzer M; Dru J; Han TH; Majumdar A; Evans JK; Murphy MG
J Clin Pharmacol; 2007 Jul; 47(7):834-40. PubMed ID: 17525168
[TBL] [Abstract][Full Text] [Related]
8. Establishing the dose of the oral NK1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Chawla SP; Grunberg SM; Gralla RJ; Hesketh PJ; Rittenberg C; Elmer ME; Schmidt C; Taylor A; Carides AD; Evans JK; Horgan KJ
Cancer; 2003 May; 97(9):2290-300. PubMed ID: 12712486
[TBL] [Abstract][Full Text] [Related]
9. Fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting.
Ruhlmann CH; Herrstedt J
Expert Rev Anticancer Ther; 2012 Feb; 12(2):139-50. PubMed ID: 22316362
[TBL] [Abstract][Full Text] [Related]
10. Human positron emission tomography studies of brain neurokinin 1 receptor occupancy by aprepitant.
Bergström M; Hargreaves RJ; Burns HD; Goldberg MR; Sciberras D; Reines SA; Petty KJ; Ogren M; Antoni G; Långström B; Eskola O; Scheinin M; Solin O; Majumdar AK; Constanzer ML; Battisti WP; Bradstreet TE; Gargano C; Hietala J
Biol Psychiatry; 2004 May; 55(10):1007-12. PubMed ID: 15121485
[TBL] [Abstract][Full Text] [Related]
11. Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol--EASE.
Grunberg S; Chua D; Maru A; Dinis J; DeVandry S; Boice JA; Hardwick JS; Beckford E; Taylor A; Carides A; Roila F; Herrstedt J
J Clin Oncol; 2011 Apr; 29(11):1495-501. PubMed ID: 21383291
[TBL] [Abstract][Full Text] [Related]
12. Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2018 Nov; 14(27):2849-2859. PubMed ID: 29873529
[TBL] [Abstract][Full Text] [Related]
13. Impact of 5-HT(3) RA selection within triple antiemetic regimens on uncontrolled highly emetogenic chemotherapy-induced nausea/vomiting.
Schwartzberg L; Jackson J; Jain G; Balu S; Buchner D
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):481-8. PubMed ID: 21711119
[TBL] [Abstract][Full Text] [Related]
14. Effect of aprepitant on the pharmacokinetics of the cyclin-dependent kinase inhibitor dinaciclib in patients with advanced malignancies.
Zhang D; Mita M; Shapiro GI; Poon J; Small K; Tzontcheva A; Kantesaria B; Zhu Y; Bannerji R; Statkevich P
Cancer Chemother Pharmacol; 2012 Dec; 70(6):891-8. PubMed ID: 23053255
[TBL] [Abstract][Full Text] [Related]
15. Addition of the oral NK1 antagonist aprepitant to standard antiemetics provides protection against nausea and vomiting during multiple cycles of cisplatin-based chemotherapy.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Carides G; Elmer M; Schmidt C; Evans JK; Horgan KJ
J Clin Oncol; 2003 Nov; 21(22):4105-11. PubMed ID: 14559891
[TBL] [Abstract][Full Text] [Related]
16. A phase 3, randomized, double-blind study of single-dose fosaprepitant for prevention of cisplatin-induced nausea and vomiting: results of an Indian population subanalysis.
Maru A; Gangadharan VP; Desai CJ; Mohapatra RK; Carides AD
Indian J Cancer; 2013; 50(4):285-91. PubMed ID: 24369195
[TBL] [Abstract][Full Text] [Related]
17. Imaging substance P receptors (NK1) in the living human brain using positron emission tomography.
Hargreaves R
J Clin Psychiatry; 2002; 63 Suppl 11():18-24. PubMed ID: 12562139
[TBL] [Abstract][Full Text] [Related]
18. Safety Profile of HTX-019 Administered as an Intravenous Push in Cancer Patients: A Retrospective Review.
Walton GD
Adv Ther; 2019 Mar; 36(3):662-669. PubMed ID: 30706408
[TBL] [Abstract][Full Text] [Related]
19. HTX-019 via 2-min injection or 30-min infusion in healthy subjects.
Ottoboni T; Lauw M; Keller MR; Cravets M; Manhard K; Clendeninn N; Quart B
Future Oncol; 2019 Mar; 15(8):865-874. PubMed ID: 30574797
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetics of aprepitant and dexamethasone in the prevention of chemotherapy-induced nausea and vomiting.
Nakade S; Ohno T; Kitagawa J; Hashimoto Y; Katayama M; Awata H; Kodama Y; Miyata Y
Cancer Chemother Pharmacol; 2008 Dec; 63(1):75-83. PubMed ID: 18317761
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
